<DOC>
	<DOCNO>NCT00097812</DOCNO>
	<brief_summary>The purpose study ass bone mineral density patient switch oral bisphosphonate zoledronic acid , compare stay oral bisphosphonate .</brief_summary>
	<brief_title>Switching Osteoporosis Patients Currently Oral Bisphosphonate Zoledronic Acid</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Postmenopausal woman 45 79 year age Must osteopenic/osteoporotic Treatment oral bisphosphonate least 1 year Any woman child bear potential Treatment bone active agent Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>osteoporosis , osteopenia , post-menopausal , zoledronic acid</keyword>
</DOC>